Introduction
Environmental chemicals with widespread human exposure, such as bisphenol A (BPA), may play an important role in deregulating normal metabolism (vom Saal et al. 2012) . BPA is used in the manufacture of poly carbonate plastic (Fleisch et al. 2010; Rubin 2011) and has been detected in food, water, and dust (Vandenberg et al. 2007) . Human exposure to BPA is demonstrated by its ubiq uitous detection in blood, urine, and adipose tissue (Dekant and Völkel 2008; Vandenberg et al. 2010) , and it has been linked to modu lation of adipocyte differentiation and obesity (Bhandari et al. 2013; Harley et al. 2013; Masuno et al. 2005; Somm et al. 2009; Wang et al. 2013) .
In vivo, BPA is rapidly conjugated to glucuronide, giving rise to BPAglucuronide (BPAG) after passing through the liver (Knaak and Sullivan 1966; Pottenger et al. 2000) . The metabolism of BPA in rat, monkey, and human hepatocytes displays some species specificity; however, BPAG has been shown to be BPA's major metabolite (Kurebayashi et al. 2010) . BPAG is excreted primarily in the urine in humans and the bile in rodents (Inoue et al. 2001 (Inoue et al. , 2003 Völkel et al. 2002) . BPAG has been detected in human serum and urine at higher concentra tions than free BPA itself (Harthé et al. 2012; Liao and Kannan 2012; Smith and Saggerson 1979) . In addition, BPAG but not free BPA was detected in blood of humans exposed to low doses of BPA (Völkel et al. 2002) . BPAG has also been investigated in a number of animal models. In rats orally administered BPA (100 mg/kg) over 6 days, the major form of BPA in the urine, milk, and plasma was BPAG (Snyder et al. 2000) . Moreover, pregnant sheep exposed to BPA showed a 1,300fold higher BPAG accu mulation in amniotic fluid and cord blood compared with BPA (Viguié et al. 2013) .
It has been the longheld belief that BPAG, the predominant metabolite of BPA exposure, has no bioactivity and is quickly eliminated in vivo. This is mainly due to the fact that BPA is wellknown for its estrogenic activity, whereas BPAG has been shown to lack the ability to activate the estrogen receptor (ER) (Matthews et al. 2001) . In HepG2 human hepatoma cells, ERα and ERβ activity was not significantly affected after exposure to BPAG (Snyder et al. 2000) . However, free BPA has been shown to possess bioactivity beyond estrogenicity, and there fore it would be reasonable to assume that BPAG could potentially influence alternate pathways much like BPA does. We and others have previously shown that BPA is a signifi cant inducer of adipo genesis in both rodent and human cell models, independent of its estrogenic activity Sargis et al. 2010) . BPA has been linked to activation of the gluco corticoid receptor (GR) as well as the thyroid receptor (TR), androgenreceptor (AR), and estrogenreceptorrelated (ERR) γ (Lee et al. 2003; Matsushima et al. 2007; Moriyama et al. 2002; Sargis et al. 2010) . The effect of BPAG on anything other than estro genic activity and on other receptors has not been determined.
In the present study, the effect of BPAG on the differentiation of the murine 3T3L1 preadipocyte cell line and primary human preadipocytes was examined. We observed that BPAG was not an inactive metabolite but was able to induce lipid accumulation in both human and murine preadipocytes and to increase expression of several key adipo genic markers at the mRNA and protein levels. Moreover, BPAG-induced differentiation was inhibited in the presence of the specific ER antagonist fulvestrant (ICI182780; ICI), despite the fact that BPAG has no estro genic activity in these cells, suggesting that a potential mechanism of BPAG action may be through a non classical ER action or as yet unknown pathway.
Materials and Methods
Adipocyte differentiation. 3T3L1 mouse embryo fibroblasts (ATCC) were cultured according to the supplier's instructions and were not used past passage 10. Cells were cultured in Dulbecco's Modified Eagles Medium (DMEM)/low glucose media containing 10% bovine calf serum (HyClone Laboratories). Two days after reaching confluence, cells were cultured in differen tiation medium consisting of DMEM, 10% fetal bovine calf serum (FBS), 500 μM 3isobutyl1methylxanthine (IBMX) Background: Exposure to common environmental substances, such as bisphenol A (BPA), has been associated with a number of negative health outcomes. In vivo, BPA is rapidly converted to its predominant metabolite, BPA-glucuronide (BPA-G), which has long been believed to be biologically inactive because it lacks estrogenic activity. However, the effects of BPA-G on cellular metabolism have not been characterized. In the present study we examined the effect of BPA-G on adipogenesis. Methods: The effect of BPA-G on the differentiation of human and 3T3L1 murine preadipocytes was evaluated in vitro by quantifying lipid accumulation and the expression of adipogenic markers. results: Treatment of 3T3L1 preadipocytes with 10 μM BPA-G induced a significant increase in lipid accumulation, mRNA expression of the adipogenic markers sterol regulatory element binding factor 1 (SREBF1) and lipoprotein lipase (LPL), and protein levels of LPL, aP2, and adipsin. Treatment of primary human preadipocytes with BPA-G also induced adipogenesis as determined by aP2 levels. Co-treatment of cells with the estrogen receptor (ER) antagonist fulvestrant (ICI) significantly inhibited the BPA-G-induced increase in LPL and aP2 levels, whereas treatment with ICI alone had no effect. Moreover, BPA-G did not display any significant estrogenic activity. conclusions: To our knowledge, this study is the first to report that BPA-G induces adipocyte differentiation and is not simply an inactive metabolite. The fact that BPA-G induced adipogenesis and was inhibited by an ER antagonist yet showed no estrogenic activity suggests that it has no classical ER transcriptional activation function and acts through a pathway that remains to be determined. SigmaAldrich), 100 nM insulin (Roche Diagnostics), and varying concentrations of BPAG (Toronto Research Chemicals Inc.) or 250 nM dexamethasone (DEX) (Sigma Aldrich). Media containing insulin with or without BPAG were replenished every 2 days. For the ER and GR antagonist studies, 0.01-10 μM ICI or 1 μM of the GR antagonist RU486 or 1 nM estradiol (E2) (all from SigmaAldrich) were also added to the cells with or without BPAG. Primary human preadipocytes (Zenbio Inc.) from donors with body mass indexes < 24.99 and who gave informed consent were maintained in Preadipocyte Medium (ZenBio). For differen tiation, confluent preadipocytes were treated with media containing 33 μM biotin, 17 μM pantothenate (SigmaAldrich), and 100 nM insulin for 14 days. In addition, 500 μM IBMX was also included in the differentiation media from day 0 to day 4. From day 2 until day 14, 5 μM troglitazone (SigmaAldrich) and the indicated concentrations of BPAG or 1 μM DEX (as a positive control) were also included in the differentiation media and replenished every 2 days. Ethics approval for the use of primary human adipocytes was obtained from the Health Canada Research Ethics Board.
In Vitro Effects of Bisphenol
Lipid staining and quantification. Clear bottomed black 96well plates were coated with rat collagen I (Invitrogen) at 5 μg/cm 2 in 0.02 M acetic acid for 1 hr at room tempera ture. 3T3L1 cells were seeded and differenti ated as described above for 8 days with the indicated treatments. Cells were then fixed with 10% formalin and stained with Nile red and DAPI (both 1 μg/mL) in 0.2% Triton phosphatebuffered saline (PBS) for 15 min as previously described (Greenspan et al. 1985) . Nile red (staining for lipid droplets) was viewed at 530 nm and DAPI (staining for cell nuclei) at 405 nm using fluorescence imaging on an Olympus IX71 microscope. Cells were imaged at 100× magnification. Nile red fluorescence was quantified at 485/528 nm (excitation/emission) and normalized to DAPI staining measured at 360/460 nm using a Synergy 2 Microplate Reader (BioTek Instruments Inc.).
Real-time polymerase chain reaction (PCR). We used the the RNeasy Kit (Qiagen) to extract total RNA from differentiating cells treated as described above. Genomic DNA was eliminated using the RNaseFree DNase Kit (Qiagen). RNA (250-500 ng) was reverse transcribed into cDNA using iScript Advanced cDNA Synthesis Kit (BioRad). For each realtime PCR reaction, cDNA was amplified in a CFX96PCR Detection System using the iQ SYBR SsoFast EvaGreen Supermix (BioRad). The primer pairs for each gene target were C/EBP α: (CCAAT/enhancerbinding protein α):
forwardTAAC TCCC CCAT GGAG TCGG, reverseTATA GACG TCTC GTGC TCGC; LPL (lipo protein lipase): forwardGATC CGAG TGAA AGCC GGAG, reverseTTGT TTGT CCAG TGTC AGCC A; SREBF1 (sterol regulatory element binding factor 1): forwardCTTT TCCT TAAG GTGG GCCT, reverseAGCT GGAG CATG TCT TCGA T; PPARγ 1/2 (peroxisome proliferatoractivated receptor γ 1/2): forwardGCCT GCGG AAGC CCTT TGGT, reverseGCAG TTCC AGGG CCTG CAGC; aP2: forwardGGAA GCTT GTCT CCAG TGAA, reverse
G C G G T G A T T T C A T C G A A T T C ;
Adipsin: forwardCCTG AACC CTAC AAGC GATG, reverseCAAC GAGG CATT CTGG GATA G; Perilipin: forwardTTGG GGAT GGCC AAAG AGAC, reverseCTCA CAAGG CTTG GTTT GGC; and β-actin: forwardGACT TCGA GCAA GAGA TGGC, reverseCCAG ACAG CACTG TGTTG GC. Standard curves were generated from the pooled cDNA obtained from cells treated with DEX from various time points. Primer efficiencies were > 90%, and specificity was confirmed by sequence blast and melting curve analysis. Reactions were normalized to βactin expression, which was not affected by BPAG treatment.
Western blot analysis. Cells were lysed in RIPA buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% sodium deoxycholate, 2% NP40, 0.4% SDS, 10% glycine) containing protease inhibitors (Roche Diagnostics). Primary antibodies for aP2 and LPL (both from R&D Systems), adipsin (Santa Cruz Biotechnology), and βactin (13E5; Cell Signaling Technology), as well as appropriate horseradish peroxidase-labeled secondary antibodies were used. Blots were developed using Clarity Western ECL Substrate (BioRad). Western blots were visu alized usingChemiDoc Imager and quantified using Image Lab software (BioRad). Protein levels were normalized using βactin.
ER and GR transcription assays. 3T3L1 cells were plated in triplicate in 12well cell culture plates in 10% charcoal stripped serum (Wisent) and phenol red-free DMEM (Wisent) media. After 24 hr, the cells were transfected with 3X ERE (estrogenresponsive element)-TATAluciferase reporter plasmid (ERELuc) and ERα and ERβ expression plasmids (pVP16ERα and pVP16ERβ, respectively) (all from Addgene) using Fugene HD (Roche Diagnostics) according to the manufac turer's instructions. The cells were transfected with 125 ng of the reporter plasmid, 25 ng ERexpression plasmid, and 10 ng pRLCMV (Promega) used as an internal control. For the GR transcription assays, experiments were performed in Cos7 cells, which were transfected as described above with either 125 ng 3XGREluc (GRresponsive element) or 125 ng aP2luc (plasmid containing the aP2 promoter region upstream of luciferase , 25 ng pTL2GR (a GR expression plasmid), and 10 ng pRLCMV as an internal control. Twentyfour hours after transfection, cells were treated with ethanol (vehicle control), 10 μM BPAG, 250 nM DEX, 1 μM RU486 (GR antagonist), or cotreatment conditions for 24 hr. Cells were then lysed in Passive Lysis Buffer (Promega), and luciferase activity was quantified with the Dual Luciferase Assay kit (Promega) using a Glomax96 Luminometer (Promega). Luciferase activity was normalized to the internal control.
Statistical analyses. Data were analyzed by Student's ttest or analysis of variance (ANOVA) with HolmSidak posttest analysis using SigmaPlot 11.0 (Systat Software Inc.).
Results
Effects of BPA-G on lipid accumulation and expression of adipo genic markers in 3T3L1 preadipocytes. We evaluated the effect of BPAG on adipocyte differentiation by assessing lipid accumulation using Nile red staining and quantification. 3T3L1 cells treated with 0.01-10 μM BPAG for 8 days showed increased Nile red lipid staining, indicating more differentiation compared with control cells treated with vehicle alone (ethanol) ( Figure 1A ). In cells treated with DEX as a positive control, roughly 90-100% of the cells were positive for lipid staining, indicating a high degree of adipocyte differ entiation. Quantification of Nile red staining showed significant lipid accumulation at 10 μM BPAG ( Figure 1B) , inducing a 3fold increase in fluorescence levels relative to control. Cells treated with DEX exhib ited an almost 8.3fold increase in lipid accumulation. No cell death was observed under any of the treatment conditions. To further evaluate BPAG-induced effects on differentiation, we used quantitative real time PCR to evaluate mRNA expression of key adipo genic factors on day 6 post treatment in response to increasing doses of BPAG (0.25-10 μM). Treatment of cells with 10 μM BPAG resulted in a statistically signifi cant increase in the mRNA levels of the adipo genic markers SREBF1 and LPL by 1.5fold the level of control ( Figure 1C) . We also measured the mRNA expression of several adipo genic markers throughout the course of differentiation at days 2, 4, 6, and 8 for all doses of BPAG, as well as for 250 nM DEX (positive control), and observed modest increases in LPL and SREBF1 mRNA levels by day 6 after BPAG treatment (see Supplemental Material, Figure S1 ). The data show that BPAG can induce adipocyte differentiation and lipid accumulation in a timedependent manner.
Effects of BPA-G on protein expression of adipo genic markers. The effects of BPAG treatment on the protein levels of the adipo genic markers LPL, aP2, and adipsin were evaluated. The data show that levels of these three proteins were significantly increased on day 8 only with 10 μM BPAG and DEX relative to the control (Figure 2A-D) . The effect of BPAG on the differentiation of primary human preadipocytes was also evalu ated. The data showed that treatment of cells with 0.05 and 0.25 μM significantly stimu lated adipocyte differentiation, as determined by aP2 protein levels ( Figure 2E,F) . These results clearly show that BPAG induced expression of some key adipo genic markers at both the mRNA and protein levels during adipocyte differentiation in 3T3L1 murine and primary human preadipocytes.
The effects of the ER antagonist ICI on BPA-G-induced differentiation. Given that the parent compound (BPA) has ER binding activity at concentrations as low as 0.1 μM (Li et al. 2012) , the potential role of the ER in BPAG-induced differentiation was investigated using the specific ER antagonist ICI. We determined lipid accumulation in 3T3L1 cells treated with vehicle (control), 1 μM ICI, 10 μM BPAG, or 10 μM BPAG plus increasing concentrations of ICI. The data show that ICI alone did not induce significant lipid accumulation, whereas 10 μM BPAG induced an increase to about 2.5fold the level of control ( Figure 3A,B) . ICI significantly inhibited BPAG-induced lipid accumulation at 1 and 10 μM ICI. Protein levels of adipo genic markers were also examined following treatment with 1 nM E2 or BPAG with or without ICI. ICI significantly inhibited BPAG-induced LPL and aP2 protein levels by 75% (to background levels) ( Figure 3C,D) . ICI also appeared to inhibit adipsin expres sion; however, the decrease in protein levels was not statistically significant due to greater variation in the Western blots. ICI or E2 alone had no effect on differentiation, consistent with previous reports ). We next confirmed that BPAG does not have estrogenic activity using cells transiently trans fected with an EREluciferase reporter plasmid.
Data show that E2, used as a positive control, signifi cantly stimulated EREluciferase activity at concentrations of 0.0001-0.01 μM, whereas BPAG had no effect on EREluciferase activity ( Figure 4A ). The ability of ICI to inhibit E2dependent luciferase activity was confirmed ( Figure 4B ).
The effects of BPA treatment on GR transcriptional activity. Cos7 cells trans fected with GR and a GREluciferase reporter plasmid were treated with either BPAG or DEX, and luciferase activity was quantified. The data show that the GR agonist DEX was able to significantly induce luciferase expression; however, treat ment of cells with 10 μM BPAG had no effect on GREcontrolled luciferase activity ( Figure 4C ). An aP2promoter reporter assay was also used to evaluate the effect of BPAG on the ability of GR to regulate the aP2 promoter. DEX significantly stimulated aP2 luciferase activity in the presence of GR, and this effect was inhibited by cotreatment with the GRantagonist RU486 ( Figure 4C ). However, treatment of cells with BPAG Figure S2 ). RU486 alone upregulated protein levels of LPL, aP2, and adipsin, as does BPAG; however, cotreatment of BPAG and RU486 had no inhibitory effect. Therefore, it is unlikely that BPAG-induced adipo genesis is mediated via the GR.
Discussion
To our knowledge, the present study is the first to show that BPAG is not an inactive metabolite, as previously believed, but is in fact biologically active and can induce lipid accu mulation and differentiation of preadipocytes in murine and primary human cell models. It has been the longheld belief that the predomi nant metabolite of BPA, BPAG, is inactive and quickly eliminated in vivo. However, the only studies that specifically examined the effects of BPAG on any cellular or physiolog ical response showed that it had no estrogenic activity, unlike its free precursor BPA, which is well known to have weak estrogenic properties (Matthews et al. 2001 ). However, BPA itself has been shown to be much more than just an estrogenic compound able to influence several signaling pathways such as GR, ERRs, androgen receptor, and TR, in addition to the traditional ERs (Lee et al. 2003; Matsushima et al. 2007; Moriyama et al. 2002; Sargis et al. 2010) . Also, we and others have previously shown that BPA can induce differentiation of preadipocytes in rodent and human models Sargis et al. 2010; Wang et al. 2013) . Only one study that we are aware of suggested that BPAG may have a physio logical effect (Weinberger et al. 2014) ; however, that study reported the effect of total BPA (both free BPA and BPAG) and did not distinguish between the two forms. Weinberger et al. (2014) showed that total BPA concentrations in pregnant mothers were associated with reductions in gestation likely due to BPA/BPAG-induced alterations in signaling via PPARγ or androgen precursors during pregnancy, suggesting an effect on the key adipo genic factor PPARγ. Therefore, it is possible that BPAG may also bind and exert effects through these other receptors.
The fact that we found BPAG to be an active compound in adipo genesis suggests that it may have effects on other cellular processes warranting further study because BPAG is the predominant metabolite following BPA exposure.
In the present study, we observed that BPAG induced adipocyte differentiation and mRNA expression of the key adipo genic factors SREBF1 and LPL, as well as aP2, LPL, and adipsin protein levels. We also found that BPAG increased protein levels of the adipocyte marker aP2 in primary human preadipocytes. Future work will further charac terize the effect of BPAG on adipo genesis in these human cells. Consistent with previous reports, we also observed no ERmediated transcriptional activity of BPAG. Interestingly, the increase in mRNA expression of the key adipocyte transcription factors CEBPα and PPARγ in response to BPAG was not statistically significant, unlike the increase in SREBF1 and LPL expression, both of which play important roles in the determination of the mature adipocyte phenotype. The concen trations of BPAG used in this study are within the range of those used in other in vitro studies and found in human and animal fluids (Kosarac et al. 2012) . BPAG has been measured in urine of newborn infants in a small study of 12 infants, with an average concentration of approximately 2 nM (0.87 ng/mL) (Nachman et al. 2013) , and was also detected (along with free BPA and BPA sulfate) in midgestation fetuses in a U.S. population of pregnant women (Gerona et al. 2013) . Harthé et al. (2012) also reported BPAG in human urine samples, with an average concentration of 11.5 nM (4.64 μg/L), similar to the in vitro concen tration of BPAG reported in ERresponsive transcription assays (Matthews et al. 2001) and the concentration used in this study. Free BPA has been shown to activate both ERα and ERβ (Hiroi et al. 1999) as well as ERRγ (Okada et al. 2008) . Previous studies found that BPAG did not bind human ERα or ERβ in vitro nor stimulate ERα or β activity in MCF7 cells at concen trations of 10 μM (Matthews et al. 2001) . Consistent with these reports, we observed that BPAG did not stimulate ERresponsive activity in 3T3L1 preadipocytes. Surprisingly, BPAG-induced adipo genesis was inhib ited by the ERantagonist ICI at 1 and 10 μM concentrations. At 10 μM ICI, lipid Figure 3A/B) ; however, at such a high concentration, ICI likely has nonspecific effects that may affect the ability of the cells to differentiate. Furthermore, all experiments were completed in 10% FBS, which contains some estrogen and estrogenlike compounds. Therefore, ICI would be expected to result in a slight inhibition compared with control. We previ ously reported that ICI was able to inhibit BPAinduced adipo genesis in primary human preadipocytes ) despite the fact that E2 did not have a positive effect on adipocyte differen tiation and is considered to be anti adipo genic (Okazaki et al. 2002) . Interestingly, it has been shown that dieth ylstilbestrol, a potent ERα activator, was adipo genic in mice and 3T3L1 cells and that the effect could be inhibited by ICI (Hao et al. 2012) . The ability of ICI to inhibit the effects of free BPA on ERα and ERβ activa tion was also reported in HepG2 and HeLa cells (Li et al. 2012) . The data therefore suggest that BPAG may assert effects on adipo genesis through an indirect inter action with the ER pathway or an as yet unidenti fied nuclear receptor that can be inhibited by ICI. One other possibility is that BPAG may be regulating adipo genesis via nuclear recep tors from the ERR family, which are known to have a role in adipo genesis (Ijichi et al. 2007) . ERRα has been shown to upregulate PPARγ coactivator1α (PGC1α) expression and PPARγ/PGC1α and SREBF1/PGC1α dimers, which are important adipo genic tran scription factors (Ju et al. 2012) . Moreover, free BPA has been shown to bind strongly to ERRγ (Abad et al. 2008; Matsushima et al. 2007 ). However, the ability of BPAG and ICI to affect the activity of ERR proteins has yet to be determined. Some reports have also suggested that free BPA mediates adipo genesis through binding and activation of the GR (Sargis et al. 2010) , and we have shown that BPA upregulated adipo genesis in the absence of glucocorticoids . The present study clearly shows that BPAG can partially replace the effect of DEX, a potent GR agonist, to induce the differentiation of 3T3L1 cells because differentiation is induced in the absence of a GR agonist. Moreover, GRmediated upregulation of aP2 promoter luciferase activity was not increased by BPAG or inhib ited by the GRantagonist RU486, further suggesting that the effect is not mediated via GR. Free BPA has also been shown to bind TR and the androgen receptors (Lee et al. 2003; Matsushima et al. 2007; Moriyama et al. 2002) , which may play roles in adipo genesis and could be potential binding partners for BPAG, warranting further study.
Only one study has examined binding of BPAG to other cellular proteins, and that report evaluated the speciesspecific differ ences in transport and metabolism of BPA and BPAG by rat and human ATPbinding cassette (ABC) transporters, which can interact with both chemicals (Mazur et al. 2012) . Due to the importance of certain ABC transporters in cholesterol and phospholipid uptake and excretion, perhaps the binding of the transporter to BPAG or free BPA may play a role in lipid metabolism and adipo genesis; however, this remains to be evaluated.
Conclusions
To our knowledge, the present study shows for the first time that BPAG is biologically active and promotes adipocyte differentiation and lipid accumulation in vitro. Our results indicate that while BPAG did not have estrogenic activity, BPAG-induced adipo genesis was still inhibited by an ER antagonist, suggesting the possibility that it may be acting through a non classical ER action or as yet unidentified pathway. Future studies will examine the potential roles of other nuclear receptors that might bind BPAG and potentially activate adipocyte differentiation.
